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Abstract
Objective: To report the prevalence of cardiometabolic risk factors in a cohort of adults with cerebral palsy (CP) and to investigate the ability of
anthropometric measures to predict these factors.
Design: Cross-sectional study.
Setting: Testing took place in a laboratory setting.
Participants: Adults with CP (NZ55; mean age, 37.513.3y; Gross Motor Function Classification System levels, IeV) participated in this study.
Interventions: Not applicable.
Main Outcome Measures: Total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, triglycerides, glucose,
insulin, and C-reactive protein levels were measured from a fasting venous blood sample. Insulin resistance was calculated using the Homeostasis
Model Assessment (HOMA-IR) index. Blood pressure, body mass index (BMI), waist circumference (WC), waist-hip ratio, and waist-height ratio
were also measured. The metabolic syndrome (MetS) was defined according to the 2009 Joint Interim Statement.
Results: The prevalence of the MetS was 20.5% in ambulatory adults and 28.6% in nonambulatory adults. BMI was associated with HOMA-IR
only (bZ.451; P<.01). WC was associated with HOMA-IR (bZ.480; P<.01), triglycerides (bZ.450; P<.01), and systolic blood pressure
(bZ.352; P<.05). Receiver operating characteristic curve analysis revealed that WC provided the best indication of hypertensive blood pressure,
dyslipidemia, HOMA-IR, and the presence of multiple risk factors (area under the curve, .713e.763).
Conclusions: A high prevalence of the MetS was observed in this relatively young sample of adults with CP. WC was a better indicator of a
number of risk factors than was BMI and presents as a clinically useful method of screening for cardiometabolic risk among adults with CP.
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ª 2014 by the American Congress of Rehabilitation Medicine Open access under CC BY-NC-ND license.Although cerebral palsy (CP) is a nonprogressive disorder, it is
well reported that adults with CP develop secondary conditions
with age including pain, stiffness, and poor balance.1,2 These
conditions contribute to a decline in physical functioning,1 loss of
mobility,1 and physical inactivity3 from early adulthood. Inactivity
in typically developing adults is associated with an increased risk
of developing type 2 diabetes mellitus, the metabolic syndrome
(MetS), and a number of individual cardiometabolic risk fac-
tors.4,5 If similar associations exist in adults with CP, they may be
at an increased risk of developing cardiovascular disease and type
2 diabetes mellitus. Indeed, a 2- to 3-fold greater mortality rate asDisclosures: None.
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Opea result of coronary heart disease was reported among adults with
CP compared to adults without CP.6 In addition, a recent study
reported that a number of cardiovascular risk factors were present
among a sample of relatively young adults with CP, the mean age
being 36.6 years.7 Despite this evidence, there are currently no
national screening programs that monitor cardiometabolic risk in
persons with CP. Screening and preventive programs are a vital
component of reducing the prevalence of cardiovascular disease
and type 2 diabetes mellitus worldwide, which should be imple-
mented before the process of atherosclerosis has progressed to an
advanced stage.
Obesity is an independent risk factor for cardiovascular disease
mortality.8,9 The relationship between obesity and cardiovascularn access under CC BY-NC-ND license.
Cardiometabolic risk in adults with cerebral palsy 1541disease is mediated through the negative effect of excess visceral
adiposity on risk factors such as blood pressure, blood lipids, in-
sulin resistance, plasma glucose, and inflammatory markers.10
Accurate screening of obesity in adults with CP is an important
step toward identifying those with an increased risk of cardio-
vascular disease. Although body mass index (BMI) is historically
used to classify obesity, a significant limitation of BMI is its
inability to differentiate between an elevated body fat content and
increased muscle mass. Normal-weight obesity (ie, people who
have a normal weight based on BMI cutoff points but a high body
fat content) is strongly associated with cardiometabolic dysregu-
lation, a high prevalence of the MetS, and an increased risk of
cardiovascular disease mortality.8 The ability of BMI cutoff points
to identify cardiometabolic risk may be particularly compromised
in adults with CP, a population known to have reduced mus-
cle mass.11
Using a criterion standard measure of body fat, such as mag-
netic resonance imaging, abdominal computed tomography, and
dual-energy X-ray absorptiometry, is not always feasible in a
clinical setting. Simple anthropometric measures such as waist
circumference (WC), waist-hip ratio (WHR), and waist-height
ratio (WHtR) have therefore been adopted as indicators of
abdominal adiposity in the general population. Not only are these
measures quick and easy to use, but research suggests that they are
superior tools, in comparison to BMI, for identifying car-
diometabolic risk.12,13 This may be true because they provide an
indicator of visceral adipose tissue, which is strongly associated
with cardiometabolic risk factors and type 2 diabetes mellitus.14
Only 1 study has specifically investigated the ability of anthro-
pometric measures to predict cardiometabolic risk in adults with
CP.15 In this study, WHR was found to be a significant predictor of
high-density lipoprotein cholesterol (HDL-C), total cholesterol
(TC)/HDL-C ratio, and triglycerides. The association between
anthropometric measures and other cardiometabolic risk factors,
however, in particular blood pressure, insulin resistance, glucose,
and inflammatory markers, has not been investigated in adults
with CP. The purpose of this study was to report the prevalence of
cardiometabolic risk factors in a cohort of adults with CP and to
investigate the ability of simple indicators of adiposity to predict
these factors.
Methods
Fifty-five adults with CP, in levels I to V of the Gross Motor
Function Classification System (GMFCS) (31 men and 24 women;
mean age, 37.513.3y; range, 18e65y), were recruited from the
Central Remedial Clinic, a national center for the treatment andList of abbreviations:
BMI body mass index
CP cerebral palsy
CRP C-reactive protein
GMFCS Gross Motor Function Classification System
HDL-C high-density lipoprotein cholesterol
HOMA-IR Homeostasis Model Assessment of insulin resistance
LDL-C low-density lipoprotein cholesterol
MetS metabolic syndrome
ROC receiver operating characteristic
TC total cholesterol
WC waist circumference
WHR waist-hip ratio
WHtR waist-height ratio
www.archives-pmr.orgcare of people with disabilities, and through general practitioners
nationwide. The GMFCS is a 5-point scale that distinguishes
between levels (IeV) of motor function on the basis of functional
mobility and the need for assistive technology, particularly
mobility aids.16 Adults with a severe intellectual disability (in-
telligence quotient <35) and pregnant women were excluded from
participating in this study.
The register of the center was searched for eligible persons,
resulting in study invitations being sent to 263 adults with CP.
Forty-three adults with CP responded and consented to participate.
Information about the study and a request to recruit eligible per-
sons was sent to 1367 general practitioners; 7 participants were
recruited by this method. The remaining participants were
recruited by word of mouth. Ethical approval for this study was
granted by the Faculty of Health Sciences’ ethics committee and
the Central Remedial Clinic’s ethics committee. All participants,
and their guardians in the case of adults with mild-to-moderate
intellectual disability, provided written informed consent before
data collection.
Measurements
Anthropometric measures
Anthropometric measures including stature, body mass, WC, and
hip circumference were obtained. In the case of nonambulatory
participants, stature was predicted from knee height.17 Knee height
wasmeasuredwith the knee and ankle held at 90, from the posterior
surface of the thigh, just proximal to the patella, to the sole of the
foot, using calipers. WC was measured, on bare skin, to the nearest
0.1cmmidway between the lower ribmargin and the iliac crest at the
end of gentle expiration. Hip circumference was measured to the
nearest 0.1cm at the end of gentle expiration around the maximum
circumference of the buttocks. WC and hip circumference were
measured on ambulatory participants in standing and on non-
ambulatory participants in supine lying positions. The mean of 2
measurements was calculated for both WC and hip circumference.
Overweight and obesity were defined as BMI 25kg/m2 and
30kg/m2, respectively. Central obesity was defined asWC80cm
and 94cm for women and men, respectively.18
Cardiometabolic risk factors
Blood pressure was measured from the right arm or the least
affected side, in the case of significant asymmetry, using the
Omron 705 IT blood pressure monitor.a The Omron 705 IT has
demonstrated excellent validity in adults.19 Participants rested in a
seated position with their backs supported for at least 5 minutes
before 3 measurements were taken at 1- to 2-minute intervals. The
average of the last 2 measurements was used in data analysis.
Hypertensive blood pressure was defined as systolic blood pres-
sure 140mmHg or diastolic blood pressure 90mmHg.20 People
who reported taking any hypertension-lowering medication were
automatically classified as hypertensive.
Blood was drawn following an overnight fast (10h) and pro-
cessed according to standard procedures in the Biochemistry
Department, St James’s Hospital, Dublin. Insulin level was
measured by using the electrochemiluminescence immunoassay
(Elecsys Insulin Assayb). Enzymatic, colorimetric assays (Roche/
Hitachi cobas c systemsb) were used to measure fasting glucose,
TC, HDL-C, and triglyceride levels. Low-density lipoprotein
cholesterol (LDL-C) level was calculated using the Friedewald
equation.21 High-sensitivity C-reactive protein (CRP) level was
measured by using particle-enhanced immunoturbidimetric assay
1542 J.M. Ryan et al(Roche/Hitachi cobas c systems). TC/HDL-C ratio was also
calculated.
The MetS was defined according to the most recent Joint
Interim Statement.18 To evaluate insulin resistance, the Homeo-
stasis Model Assessment (HOMA-IR) index22 was used. Insulin
resistance was defined by the 75th percentile of the HOMA-IR
index of the participants being studied (HOMA-IR
indexZ2.51).23 The presence of elevated levels of TC, LDL-C,
triglycerides, and low HDL-C was defined according to the
National Cholesterol Education Program, Adult Treatment Panel
III.24 The following cutoffs were applied: hypercholesterolemia
5.2 mmol/L, high LDL-C 3.4mmol/L, hypertriglyceridemia
1.7mmol/L, and low HDL-C <1.0mmol/L. People who reported
taking any cholesterol medication were automatically classified as
having abnormal TC, TC/HDL-C ratio, HDL-C, and LDL-C.
Fasting glucose was categorized according to the cutoff point
identified by the Joint Interim Statement on the MetS (hypergly-
cemia 100mg/dL).18 High-risk CRP was categorized as
>0.3mg/dL.25
Statistical analysis
The distribution of the data was checked for normality by using
the Kolmogorov-Smirnov test. The logarithm function was
applied to TC/HDL-C ratio and HOMA-IR index to transform
these data to a normal distribution. Means and SDs were
computed for each of the normally distributed continuous vari-
ables. Medians and interquartile ranges were computed for skewed
data. Prevalence data are presented as percentages. Differences
between continuous variables with a normal distribution were
determined by using independent t tests. Differences between
continuous variables with a skewed distribution were determined
by using Mann-Whitney U tests. Pearson’s chi-square test was
used for comparison of independent groups of categorical data.
Pearson’s partial correlation test (controlled for gender) was used
to examine correlations between GMFCS level and each anthro-
pometric measure.
To determine the association between cardiometabolic out-
comes (ie, systolic blood pressure, diastolic blood pressure, TC,
HDL-C, TC/HDL-C ratio, LDL-C, triglycerides, glucose, HOMA-
IR index, CRP) and anthropometric measures (BMI, WC, WHR,
WHtR), separate multiple regression analyses were conducted for
each dependent variable (ie, cardiometabolic outcome). Age,
gender, and ambulatory status, defined as 1ZGMFCS levels I to
III and 0ZGMFCS levels IV to V, were adjusted for in each
analysis. The following model was used for all analyses: block 1:
age, gender, ambulatory status; block 2: anthropometric measure.
Each anthropometric measure was entered in a separate analysis to
avoid multicollinearity. When systolic blood pressure or diastolic
blood pressure was the dependent variable of interest, the analysis
was additionally adjusted for self-reported taking of antihyper-
tensive medication (coded as 1 if yes or 0 if no). When TC, HDL-
C, LDL-C, or TC/HDL-C ratio was the dependent variable,
additional adjustment was made for self-reported taking of
cholesterol medication (coded as 1 if yes or 0 if no). To examine
whether WC, WHR, or WHtR were associated with car-
diometabolic risk factors independent of BMI, follow-up analyses
were conducted between each cardiometabolic risk factor and
WC, WHtR, and WHR, additionally adjusting for BMI in block 1.
Variance inflation factors <5 revealed no issue with collinearity.
A receiver operating characteristic (ROC) curve analysis was
conducted to compare the anthropometric measures at predictingthe presence of individual cardiometabolic risk factors (hyper-
tensive blood pressure, hypercholesterolemia, low HDL-C, high
LDL-C, hypertriglyceridemia, hyperglycemia, high HOMA-IR
index, high-risk CRP) and the presence of 2 risk factors. An
area under the ROC curve of >.90 is considered excellent; .80 to
.90 is considered good; and .70 to .80 is considered fair. All an-
alyses were performed using Analyse-it for Microsoft Excel
(version 2.20)c and IBM SPSS Statistics (version 19).d Statistical
significance was set at P<.05.
Results
The demographic and diagnostic distribution of participants is
presented in table 1. A value for CRP and insulin was missing for 1
nonambulatory person and a value for plasma glucose was missing
for 1 ambulatory person, as a result of processing errors. One
ambulatory person reported a prediagnosis of type 1 diabetes mel-
litus. This person was removed from all analyses of blood bio-
markers of glucose metabolism (ie, plasma glucose, insulin,
HOMA-IR index) and the MetS. Hip circumference was not ob-
tained from 2 nonambulatory adults because of significant
contractures. Participants’ anthropometric measures and car-
diometabolic outcomes are presented in table 1. Within the study
cohort, BMI ranged from 12.3 to 36.8kg/m2, WC ranged from 64 to
126.5cm, WHR ranged from 0.68 to 1.11, and WHtR ranged from
.36 to .81. Four participants (7.3%) were obese according to BMI
cutoffs. The prevalence of central obesity was 36.4% (table 2). A
significant difference between ambulatory and nonambulatory
adults was observed for WHR (P<.05), HDL-C (P<.01), and TC/
HDL-C ratio (P<.05). There were no other between-group differ-
ences. Pearson’s partial correlations revealed that the GMFCS was
associated with hip circumference (rZ.356; P<.05) and WHR
(rZ.287; P<.05) when adjusted for gender.
Five adults (9.1%) were on antihypertensive medication. Five
adults (9.1%) were taking cholesterol medication. Only 1 person
reported smoking (<20 cigarettes per day). The prevalence of the
MetS in the total cohort was 22.6% (see table 2).
The significant associations between anthropometric measures
and cardiometabolic outcomes are presented in table 3. After
adjusting for age, gender, and ambulatory status, WC, WHR, and
WHtR were associated with the HOMA-IR index and triglyceride
levels. WC was also associated with systolic blood pressure. BMI
was associated with the HOMA-IR index only. WC and WHtR
remained associated with triglyceride levels when the model was
additionally adjusted for BMI. WC was also associated with
systolic blood pressure independent of BMI. The ability of BMI,
WC, WHR, and WHtR to predict the presence of cardiometabolic
risk factors, as determined by area under the curve values, is
presented in table 4. ROC curve analysis was not performed on
fasting glucose because of the small number of people defined as
having elevated fasting glucose (nZ3). The area under the curve
for hypertensive blood pressure, hypercholesterolemia, high
HOMA-IR index, high LDL-C, and the presence of 2 risk fac-
tors was highest for WC (.643e.750). Area under the curve values
for low HDL-C and high triglycerides were highest for WHtR
(.711 and .900, respectively).
Discussion
The aims of this study were to report the prevalence of car-
diometabolic risk factors in adults with CP and to investigate their
association with anthropometric measures. The prevalence of the
MetS in this relatively young cohort of adults with CP was 22.6%.www.archives-pmr.org
Table 1 Participants’ characteristics, anthropometric measures, and cardiometabolic outcomes by ambulatory status
Characteristic Total (nZ55) Ambulatory (nZ41) Nonambulatory (nZ14)
Males, females 31, 24 19, 22 12, 2
Age (y) 37.513.3 36.512.5 40.315.7
Age (y), range 18e65 18e62 18e65
Spastic CP, n (%) 49 (89.1) 37 (90.2) 12 (85.7)
Unilateral spastic 15 (30.6) 15 (40.5) NA
Bilateral spastic 34 (69.4) 22 (59.5) 12 (100.0)
Other,* n (%) 6 (10.9) 4 (9.8) 2 (14.3)
GMFCS, n (%)
I 13 (23.6) 13 (31.7) NA
II 18 (32.7) 18 (43.9) NA
III 10 (18.2) 10 (24.4) NA
IV 8 (14.5) NA 8 (57.1)
V 6 (10.9) NA 6 (42.9)
Height (cm) 163.310.0 163.910.9 161.77.0
Weight (kg) 64.914.0 65.913.1 61.916.5
BMI (kg/m2) 24.24.4 24.53.6 23.66.2
WC (cm) 83.513.4 82.911.5 85.418.1
WHR 0.870.09 0.850.09y 0.920.10y
WHtR 0.510.08 0.510.07 0.530.11
Systolic blood pressure (mmHg) 126.214.3 126.613.9 125.115.8
Diastolic blood pressure (mmHg) 76.09.8 75.79.2 76.611.9
TC (mmol/L) 4.50.9 4.60.9 4.20.9
HDL-C (mmol/L) 1.480.39 1.570.38z 1.210.29z
TC/HDL-C 3.11.3 3.01.3y 3.51.3y
LDL-C (mmol/L) 2.640.77 2.660.76 2.560.82
Triglyceridex (mmol/L) 0.80.5 0.80.4 0.81.1
Plasma glucosex (mg/dL) 84.610.8 84.610.8 84.610.8
HOMA-IR index (mU/L) 1.751.74 1.871.76 1.441.62
NOTE. Values are mean  SD or as otherwise indicated.
Abbreviations: IQR, interquartile range; NA, not applicable.
* Dyskinetic and ataxic CP were combined to form 1 group because of the small number of participants with these diagnoses.
y Between-group difference at P<.05.
z Between-group difference at P<.01.
x Variables with a skewed distribution. Values are median  IQR.
Cardiometabolic risk in adults with cerebral palsy 1543The prevalence of the MetS in ambulatory adults with CP was
similar to that reported in a population of Irish adults aged 50 to
69 years (21%)26 and American adults aged 20 years (21.8%).27
In nonambulatory adults, the prevalence of 28.6% was, however,
significantly higher than prevalence rates in the general popula-
tion. A number of individual risk factors for cardiometabolic
disease were also present in the cohort. Notably, although 15
participants (27.3%) had elevated LDL-C levels, only 5 partici-
pants were on medication for dyslipidemia. Screening for car-
diometabolic risk factors should occur in this population from
young adulthood to implement timely preventive programs.
Regardless of age, gender, and ambulatory status, WC was asso-
ciated with a number of cardiometabolic risk factors and may be
used as a quick and easy method of identifying adults with CP at
risk of developing cardiovascular disease and type 2 dia-
betes mellitus.
A recent study investigated the prevalence of cardiovascular
disease risk factors in a sample of Dutch adults with CP (mean age,
36.6y; age range, 25e45y).7 Although the prevalence of hyperten-
sive blood pressure values in the Dutch cohort was higher (25.6%)
than that in the current study, the prevalence of elevated TC, elevated
fasting glucose, and low HDL-C levels was lower (7.0%, 0.0%, andwww.archives-pmr.org11.6%, respectively) than that in the present study. This may be
because the Dutch cohort was less severely impaired compared with
the current sample (only 2 adults were nonambulatory) and the
relatively younger age range of participants.
The prevalence of obesity, defined by BMI, in the present study
(7.3%) was relatively low in comparison to a sample of Dutch
adults with CP (18.5%)7 and to the general Irish adult population
without CP (25%).28 The use of BMI as an indicator of cardio-
vascular disease risk in adults with CP has been debated, however,
given that it is unable to distinguish between body fat and muscle
mass. Adults with CP experience significant muscle atrophy,11
which may result in misclassification of overweight as normal
weight if BMI cutoff points for the general population are used to
classify overweight/obesity in adults with CP. Previous studies
investigating the association between BMI and cardiometabolic
risk factors in adults with CP have reported conflicting results.
One study reported that BMI was associated with diastolic blood
pressure and that there was a trend toward an association with 10-
year risk of fatal cardiovascular disease.7 A second study reported
that BMI was not associated with TC, HDL-C, LDL-C, TC/HDL-
C ratio, or triglycerides.15 This is in agreement with the results of
the present study. The present study is the first, however, to
Table 2 Prevalence of overweight/obesity, cardiometabolic risk
factors, and the MetS among participants
Risk Factor
Total
(nZ55)
Ambulatory
(nZ41)
Nonambulatory
(nZ14)
BMI 25kg/m2 18 (32.7) 14 (34.1) 4 (28.6)
BMI 30kg/m2 4 (7.3) 3 (7.3) 1 (7.1)
Central obesity* 20 (36.4) 15 (36.6) 5 (35.7)
Hypertensive blood
pressurey
11 (20.0) 7 (17.1) 4 (28.6)
Hypercholesterolemiaz 17 (30.9) 13 (31.7) 4 (28.6)
Low HDL-Cz 9 (16.4) 4 (9.8) 5 (35.7)
High LDL-Cz 15 (27.3) 11 (26.8) 4 (28.6)
Hypertriglyceridemia 7 (12.7) 4 (9.8) 3 (21.4)
Hyperglycemia 3 (5.7) 3 (7.7) 0 (0.0)
High-risk CRP 9 (16.4) 6 (14.6) 3 (21.4)
MetS 12 (22.6) 8 (20.5) 4 (28.6)
NOTE. Values are n (%).
* Defined as waist circumference 80cm for women or 94cm for
men.
y Including participants on antihypertensive medication.
z Including people on cholesterol medication.
1544 J.M. Ryan et alinvestigate and demonstrate an association between BMI and in-
sulin resistance in adults with CP.
Although the results of this study suggest that all anthropo-
metric measures are associated with 1 cardiometabolic risk
factors in adults with CP, ROC curve analysis indicated that WC
was the best predictor of a number of cardiometabolic risk factors.
This is in agreement with studies of the general population.12,13
WC was also associated with triglyceride levels and systolic
blood pressure independent of BMI. Unlike BMI, WC provides an
indication of visceral adipose tissue. The secretion of proin-
flammatory cytokines and adipokines from visceral adipose tissue
contributes to insulin resistance, hypertension, and dyslipidemia
and may provide the link between central obesity and cardiovas-
cular disease.29 Imaging techniques such as magnetic resonance
imaging, abdominal computed tomography, and dual-energy X-
ray absorptiometry provide accurate measurements of visceral
adipose tissue but are expensive and often unfeasible to use in theTable 3 Regression coefficients (b) showing the association between
Dependent variable Independent variable
Unstand
coefficie
HOMA-IR index WC 0.010 (0
HOMA-IR index BMI 0.027 (0
HOMA-IR index WHR 1.437 (0
HOMA-IR WHtR 1.574 (0
Triglycerides WC 0.020 (0
Triglycerides WHtR 3.033 (0
Triglycerides WHR 2.741 (1
Triglycerides* WC 0.029 (0
Triglycerides* WHtR 4.425 (1
Systolic blood pressure WC 0.376 (0
Systolic blood pressure* WC 0.599 (0
NOTE. The following model was used for all analyses: block 1: age, gender, am
measure was entered in a separate analysis to avoid multicollinearity. When
variable of interest, the analysis was additionally adjusted for self-reported
* Model additionally controlled for BMI in block 1.clinical setting. The consistent association between WC and car-
diometabolic risk factors in this study suggests that WC provides a
proxy measure of visceral adipose tissue among adults with CP
and can be used to identify those at risk of developing cardio-
vascular disease and type 2 diabetes mellitus. Defining obesity
according to WC, rather than BMI, may therefore be a more
appropriate method of classifying obesity in adults with CP.
Thresholds of 80cm for women and 94cm for men have been
proposed for classifying abdominal obesity in able-bodied adults
of European origin.18 Further research is required, however, to
validate these thresholds in adults with CP.
In agreement with previous research,15 WHR was associated
with a number of cardiometabolic risk factors. The relative pre-
dictive power ofWHR, however, was not as high as that ofWC. The
predictive power ofWHR in adults with CPmay be influenced by its
association with gross motor function. This association was a result
of the inverse relationship between hip circumference and GMFCS
leveldan expected relationship considering the positive correlation
between hip circumference, gluteal muscle, and total leg muscle
mass.30 Although some amount of muscle atrophy is present in all
adults with CP, gluteal and total leg muscle mass particularly atro-
phy in nonambulatory adults.31 As well as being associated with
gross motor function, WHR is more difficult to assess and a less
reliable measure than WC in the general population.32 Difficulty
with obtaining hip circumference measurements from non-
ambulatory participants or participants with significant contractures
may also increase the potential for error when measuring WHR in
adults with CP. In contrast, WC is a simple and feasible measure to
take on ambulatory and nonambulatory adults in a clinical setting.
Study limitations
This study has a number of limitations. Primarily, the cross-
sectional design of the study does not allow causality to be
inferred. In addition, the studied sample was relatively small and
may have influenced the estimate of cardiometabolic risk. There is
currently no CP register in the Republic of Ireland, and the ma-
jority of rehabilitative services are provided only until age 18
years. Despite every effort being made to recruit adults with CP
for this study, the low response rate may have resulted in selection
bias. In particular, adults with an interest in health promotion maycardiometabolic outcomes and anthropometric measures
ardized
nts, b (SE)
Standardized
coefficients, b P R2 change
.003) 0.501 .001 0.183
.008) 0.448 .002 0.176
.484) 0.526 .005 0.150
.459) 0.456 .001 0.184
.006) 0.450 .003 0.140
.993) 0.407 .004 0.135
.033) 0.452 .011 0.108
.012) 0.648 .016 0.090
.837) 0.593 .020 0.084
.151) 0.352 .016 0.084
.273) 0.560 .033 0.065
bulatory status; block 2: anthropometric measure. Each anthropometric
systolic blood pressure or diastolic blood pressure was the dependent
taking of antihypertensive medication (coded as 1 if yes or 0 if no).
www.archives-pmr.org
Table 4 Area under the curve values (95% confidence intervals) for anthropometric measures
Risk Factor BMI WC WHRa WHtR
Hypertensive blood pressure 0.693 (0.499e0.888) 0.747* (0.533e0.961) 0.726* (0.523e0.929) 0.694 (0.483e0.906)
Hypercholesterolemia 0.615 (0.451e0.778) 0.643* (0.479e0.808) 0.596 (0.422e0.769) 0.611 (0.443e0.778)
Low HDL-C 0.624 (0.407e0.842) 0.692* (0.522e0.862) 0.708* (0.523e0.893) 0.711* (0.513e0.909)
High LDL-C 0.666* (0.497e0.835) 0.701* (0.527e0.875) 0.688* (0.515e0.861) 0.648* (0.472e0.825)
Hypertriglyceridemia 0.754y (0.567e0.942) 0.841y (0.693e0.988) 0.757* (0.541e0.973) 0.900y (0.813e0.988)
High HOMA-IR index 0.700 (0.530e0.869) 0.721y (0.521e0.920) 0.657* (0.451e0.864) 0.671 (0.480e0.862)
High-risk CRP 0.600 (0.394e0.806) 0.570 (0.381e0.759) 0.605 (0.393e0.816) 0.567 (0.374e0.759)
2 risk factors 0.665* (0.514e0.816) 0.750y (0.609e0.892) 0.706y (0.552e0.860) 0.703y (0.552e0.853)
NOTE. The Concordance C statistic (area under the curve) and Wald 95% confidence limits are provided for each analysis.
* P<.05.
y P<.01.
Cardiometabolic risk in adults with cerebral palsy 1545have been more likely to participate. Because information was not
available on adults who did not respond to the recruitment efforts,
comparisons cannot be made between responders and non-
responders. However, it should be noted that the sample size is
similar to other studies of adults with CP. In addition, the small
sample size did not allow for adjustment for gender when con-
ducting ROC curve analysis. Only WC and WHR, however, are
known to be associated with gender, and it is unlikely that per-
forming separate analyses would change the order of the outcome.
The results of the ROC curve analysis were also supported by the
results of the regression analysis, which was adjusted for gender.
Although an attempt was made to detect differences in car-
diometabolic outcomes between ambulatory and nonambulatory
adults, it is also possible that the sample size was not adequate to
detect between-group differences.
Conclusions
The results of this study indicate that relatively young adults with
CP have clustering of cardiometabolic risk factors. Implementation
of risk factor screening and preventive strategies is required in this
population from young adulthood. WC is associated with hyper-
tensive blood pressure, dyslipidemia, and insulin resistance in
adults with CP regardless of age, gender, or gross motor func-
tioning. WC provides additional information above that obtained
from BMI. WC therefore presents as a quick and easy clinical
measure, which should be used instead of or in conjunction with
BMI, to identify adults with CP at risk of cardiovascular disease and
type 2 diabetes mellitus. Future research should validate cutoffs for
elevated waist circumference in adults with CP.
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